Skip to main content
Glama

Protein Atlas

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The annotations already cover the safety profile (readOnly, idempotent, non-destructive, open-world), and the description adds substantial behavior beyond that: fan-out across nine sources, GDELT→GNews fallback, 'an empty section is a real no-data, not a bug', the expected-empty fda_products caveat for small-molecule-only companies, and resolved:false-with-notes for private companies. This directly prevents false bug reports and misread results.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The content is dense and every major clause earns its place, but it is one long run-on paragraph with a semicolon-heavy structure that hurts scannability. The six trigger phrases at the top are redundant — two would have conveyed the same signal — and the type-interchangeability note repeats what the schema already states. Front-loaded purpose is good, but the formatting is not appropriately sized.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

This is a high-complexity tool with no output schema, so the description must carry the burden of explaining return values — and it does, enumerating every result section (cik/company_name, recent_filings with URIs, fundamentals, patents, contracts, fda_products, hiring, news, LEI, sources_used/sources_failed) plus error/edge semantics. Given its complexity, nothing an agent needs to invoke it correctly or interpret its results is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, with the enum behavior and the ticker/CIK/name formats already fully documented in the input schema, so the baseline is 3. The description mostly restates these formats with examples, adding only marginal extra value: resolved_from/resolved_to when `value` was a name and the private-company resolution outcome. It does not add format or syntax detail beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb and resource: 'full cross-source profile of a US public company in ONE parallel call', with six concrete trigger phrases that leave no ambiguity about what the tool does. The 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups' line differentiates it from the single-query siblings without needing to open any schemas.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Explicitly says when to prefer this tool ('when the user asks for a holistic view') and what to use instead (chaining single-pack lookups). It also enumerates the three accepted input shapes (ticker, CIK, company name) and the boundary case (private company → resolved:false), so an agent can route accurately before invoking.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Protein Atlas toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Several tools have overlapping purposes: ask_pipeworx, ask_pipeworx_beta (currently identical), ask_pipeworx_grounded, deep_research, and validate_claim all handle routed research queries, while ai_visibility_check and scan_competitor_ai_presence overlap directly and the six Polymarket tools form a dense, easily confused cluster. The descriptions are detailed, but an agent will frequently struggle to pick the right tool among near-duplicate research and prediction-market options.

Naming Consistency3/5

Names are readable and mostly snake_case, with useful prefixes like ask_pipeworx_ and polymarket_. However, conventions are mixed: some are verb_noun (search_genes, get_protein, generate_llms_txt), some are bare verbs (remember, recall, forget), and some are noun phrases (entity_profile, recent_changes, top_tissues). There is no single predictable pattern.

Tool Count2/5

34 tools is above the 25+ threshold for a heavy, hard-to-navigate set, and most of them are not related to the server's stated 'Protein Atlas' identity. Only three tools actually concern proteins, while the rest form a general data-research, Polymarket, memory, and subscription toolkit that feels like several servers merged into one.

Completeness2/5

For a Protein Atlas server, the surface is severely incomplete: only search_genes, get_protein, and top_tissues cover HPA, leaving pathology, cell-line, single-cell, blood, and other major HPA dimensions unaddressed. If the intended domain is instead the broader Pipeworx data router, the protein tools are an odd vestige and the completeness story is still muddled by overlapping meta-tools.

Resources